Patients with breast cancer having higher LINC01198’s expression tended to have a higher immune response indicated by higher CD8, IL-2, IL-8, and IL-12 immune signature scores (rho = 0.309, 0.374, 0.555, and 0.359, respectively; P < 0.05; Fig. 4B and fig. Here, CXCL8 is linked to breast carcinoma.